HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma.

ABSTRACT:

Purpose

In head and neck squamous cell carcinoma (HNSCC), HRAS mutation is a new actionable oncogene driver. We aimed to evaluate HRAS mutational variants, comutation profile, and survival outcomes of this molecularly defined population.

Methods

We leveraged four deidentified patient data sets with HRAS-mutant HNSCC, MD Anderson Cancer Center, Kura Oncology, Inc trial, Foundation Medicine, and American Association for Cancer Research GENIE v.12. Patient demographic information and clinical courses were extracted, when available, in addition to HRAS mutation type and co-occurring mutations. Survival outcomes were analyzed (Kaplan-Meier method).

Results

Two hundred forty-nine patients with HRAS-mutant HNSCC were identified from the fou

SUBMITTER: Coleman N 

PROVIDER: S-EPMC9928766 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature